樂德木單抗（INN：lerdelimumab；開發代號：CAT-152）是一種人單株抗體，也是一種針對轉化生長因子β2的免疫抑制劑。[1][2]
該藥物的開發是為了減少青光眼引流手術後的疤痕。[3]由於該病症的試驗結果不成功，開發於2005年底停止。[4]
參考資料[編輯]
- ^ Cordeiro, M. Francesca. Technology evaluation: lerdelimumab, Cambridge Antibody Technology. Current Opinion in Molecular Therapeutics. 2003-04, 5 (2). ISSN 1464-8431. PMID 12772512.
- ^ Mead, Anna L.; Wong, Tina T. L.; Cordeiro, M. Francesca; Anderson, Ian K.; Khaw, Peng T. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Investigative Ophthalmology & Visual Science. 2003-08, 44 (8) [2024-05-26]. ISSN 0146-0404. PMID 12882787. doi:10.1167/iovs.02-0978. （原始內容存檔於2024-05-26）.
- ^ Lerdelimumab. Drugs in R&D. 1 February 2002, 3 (2): 106–8. PMID 12001808. doi:10.2165/00126839-200203020-00006.
- ^ CAT abandons Trabio after second clinical trial failure. The Pharma Letter. 28 March 2005.
